ArticleInternational journal of cardiology. Cardiovascular risk and prevention2026
B lymphocytes and hyperglycemia synergistically exacerbate coronary in-stent restenosis.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the B-cell conundrum in in-stent restenosis.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphocytes are tightly associated with coronary artery disease (CAD). However, there is a lack of clinical evidence that lymphocyte subsets are associated with in-stent restenosis (ISR). The aim of this clinical research was to elucidate the association between these. Methods: A total of 812 patients were enrolled in the study, and they were categorized into the non-ISR group (N = 575) and the ISR group (N = 237). For each patient, the counts and percentage of CD4 Results: Compared with non-ISR group, ISR group had higher levels of B-cell% (P = 0.011), B-cell (P = 0.010), non-HDL (P = 0.006), and higher proportion of diabetes (P = 0.002). B cell% (OR 1.033, 95 %CI:1.002-1.065, P = 0.039), diabetes (OR 1.556, 95 %CI:1.134-2.134, P = 0.006), non high density lipoprotein cholesterol (non-HDL-C) (OR 1.210, 95 %CI:1.026-1.428, P = 0.024) were independent risk factors for ISR. The RCS curves showes both B cell% (P for nonlinear = 0.415; P for overall = 0.035) and non-HDL-C (P for nonlinear = 0.168; P for overall = 0.024) showed a linear upward trend consistent with ISR. Subgroup analyses suggested that high B cell% (B cell%≥12) promotes the hazardous effects of diabetes on ISR (P for interaction = 0.042), while chronic hyperglycaemia (HbA1c%≥6.6) exacerbates the ISR promoting effects of B cells(P for interaction = 0.04). Conclusion: B cells, non-HDL-C, and diabetes are closely associated with the development of ISR, and high B cell% and Hyperglycemia reciprocally promote ISR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.